Did the 2017 Kansas KDRAFT pilot study, a single‑arm three‑month trial, demonstrate reversal of dementia in any participants?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No Evidence of Dementia Reversal in the Kansas KDRAFT Pilot Study

The provided evidence does not contain any information about the 2017 Kansas KDRAFT pilot study, and therefore I cannot confirm whether this trial demonstrated reversal of dementia in any participants.

Critical Context from Available Evidence

The evidence base provided focuses exclusively on:

  • Cholinesterase inhibitors and memantine for dementia treatment 1, 2
  • Reversible dementia prevalence in clinical settings 3, 4, 5
  • Other dementia interventions unrelated to the Kansas study 6, 7, 8, 9

What We Know About Dementia Reversal

Based on the available evidence, true reversal of dementia is exceptionally rare:

  • In elderly patients referred to memory clinics, the prevalence of reversible dementia is approximately 1% when assessed by standardized measurement after treatment 3
  • Among potentially reversible dementias identified (7.2% of dementia cases), only 3.6% showed complete clinical and neuropsychological reversal after treatment 5
  • Another study found potentially reversible conditions in 19.8% of patients, but on prospective follow-up only 3.3% had reversible symptoms, and none were completely reversed 4

Important Caveats

The concept of "reversal" requires careful definition:

  • Improvement or stabilization (as measured in pharmacologic trials) is fundamentally different from true reversal
  • Standard dementia medications show statistically significant effects on cognitive scales but do not achieve clinically significant changes (e.g., donepezil showed <4-point change on ADAS-cog, below the threshold for clinical significance) 1
  • Even when "potentially reversible" causes are treated (metabolic disorders, vitamin deficiencies, depression), complete reversal is rare and partial improvement is more common 3, 5

Without access to the specific KDRAFT study data, no determination can be made about its findings regarding dementia reversal.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.